ASH 2016

The American Society of Hematology will host its 58th Annual Meeting & Exposition December 3-6, 2016, in San Diego, California. Professionals from around the world will present and discuss research on the foremost topics in malignant and non-malignant hematology. Sign up for our daily e-mail blasts on our registration page, and check back here during the conference for the full coverage.


   |    ASH 2016 > Surabhi Dangi-Garimella, PhD
Representatives from the Beat acute myeloid leukemia (AML) and National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH), which incorporate genomic profiling to assign patients to different treatment arms, provided an insight on trial design and a progress report.
   |    ASH 2016 > Surabhi Dangi-Garimella, PhD
Older patients diagnosed with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) continue to present a favorable response to single-agent ibrutinib, at a follow-up of 29 months, in phase 3 of the RESONATE-2 trial.
Pam Mangat Explains How ASCO Works to Educate Oncologists on Precision Medicine
   |    ASH 2016
Pam Mangat, MS, associate director TAPUR study at the American Society of Clinical Oncology, says that the organization has developed a number of initiatives to educate oncology practitioners on the potential of precision medicine, such as testing guidelines, online courses, a virtual tumor board, and clinical trials.
   |    ASH 2016 > Surabhi Dangi-Garimella, PhD
The Special Symposium on Quality at the 58th American Society of Hematology Annual Meeting & Exposition, looked at how health information technology can be utilized to improve healthcare quality, enhance patient-provider shared decision-making, and facilitate efforts in quality research.
   |    ASH 2016 > Surabhi Dangi-Garimella, PhD
Phase 3 results from the LyMa trial show that rituximab maintenance therapy after autologous stem cell transplant (ASCT) prolongs event-free survival, progression-free survival, and overall survival (OS) in previously untreated young patients with mantle cell lymphoma (MCL).
Dr Carrie Stricker Discusses IT Solutions That Engage Both Cancer Patients and Care Teams
   |    ASH 2016
Innovative health IT tools like those developed by Carevive help maximize the balance between patient self-management and care team engagement, which is especially important in the era of value-based care, according to Carrie Stricker, PhD, RN, AOCN, chief clinical officer and co-founder of Carevive.
Dr Joseph Alvarnas on How Comorbidities Impact Care Decisions for Cancer Patients
   |    ASH 2016
A cancer patient’s comorbid diseases have important implications for setting goals and selecting treatment, said Joseph Alvarnas, MD, of the City of Hope and editor-in-chief of Evidence-Based Oncology. Clinicians must keep comorbidities in mind as they base oncology care upon that person as an individual.
   |    ASH 2016 > Surabhi Dangi-Garimella, PhD
Early phase 1 results show that including the cyclin-dependent kinase 4/6 inhibitor palbociclib in the treatment of patients with mantle cell lymphoma (MCL) can help overcome resistance to ibrutinib.
Adult ADHD Compendium
COPD Compendium
Dermatology Compendium
Diabetes Compendium
Hematology Compendium
Immuno-oncology Compendium
Lipids Compendium
MACRA Compendium
Neutropenia Compendium
Oncology Compendium
Pain Compendium
Reimbursement Compendium
Rheumatoid Arthritis Compendium
Know Your News
HF Compendium
Managed Care PODCAST
Upcoming Partner Events
October 24-25, 2017
San Francisco, CA